The accumulation of senescent cells is a major cause of age-related inflammation and predisposes to a variety of age-related diseases1. However, little is known about the molecular basis underlying this accumulation and its potential as a target to ameliorate the ageing process. Here we show that...
Glioma treatment using a PD-1/PD-L1 blocking antibody Combination therapy strategy and preclinical research The blockade of PD-1/PD-L1 can elicit effective anti-tumor T cell responses. In the past 5 years, the targeting of the PD-1/PD-L1 axis has been at the forefront of immunotherapy due...
Pembrolizumab is a programmed death receptor-1 (PD-1) blocking monoclonal antibody. It can block the immunosuppression mediated by the PD-1 pathway through blocking the interactions between PD-1 and PD-L1/PD-L2, and play a role in tumor immune function. It was the first PD-1 inhibitor appr...
原文出处:U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon...
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells. Clin Cancer Res. 2023;29:621–34. Article PubMed Central Google Scholar Li H, Li X, Liu S, Guo L, Zhang B, Zhang J, et al. Programmed cell death-1 (PD-1) ...
In this paper, we review PD-L1 expression, PD-L1-mediated immunosuppressive mechanisms, and the clinical applications of PD-1/PD-L1 inhibitors in gliomas. Potential treatment strategies and the challenges that may occur during the clinical development of these agents for gliomas are als...
blocking antibody in this combination is not recommended outside of controlled clinical trials. Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. If used during pregnancy, or if the patient becomes pregnant during treatment, ap...
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy Encouraging results following the blockade of the PD-1/PD-L1 pathway have validated PD-L1 or PD-1 as a target for cancer immunotherapy. Studies have ... S Xue,M Hu,V Iyer,... - 《Journal of Hematology &...
4. Heinzerling, L., et al., Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer, 2016. 4: p. 50. 5. Larsen, M., V. Appay, and D. Sauce, [Influence of PD-1 on the immunological synapse: a facet of immune regulation ?]. Med Sci (Paris), 2013...
Here, we show that ex vivo co-delivery of CpG-ODN with antigen is required to generate an effective DC vaccine that synergizes with checkpoint blockers to induce long-lasting anti-tumor immunity in melanoma. Biologic therapies incorporating PD-1 blocking antibodies in immunogenic cancers like melano...